The global postoperative pain market size is estimated to be valued at US$ 38.43 billion in 2023 and is projected to surpass a valuation of US$ 63.8 billion by 2033. The adoption of postoperative pain drugs is likely to rise at a CAGR of 5.2% during the forecast period. Some major factors propelling the postoperative pain industry growth include:
These factors are propelling the major players to increase their output, which is likely to ultimately result in positive market growth for postoperative pain.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to health experts, surgery is linked to long-lasting chronic postoperative pain that typically lasts between three and six months. The demand for postoperative pain is anticipated to rise as phantom pain is one of the frequent postoperative disorders that follows breast surgery, a cesarean section, a thoracotomy, limb amputation, or inguinal hernia repair. Numerous studies carried out in nations with highly established healthcare systems have shown that between one-third and fifty percent of patients do not have adequate postoperative pain management.
The global market for postoperative pain treatments is predicted to experience growth over the forecast period due to an increase in surgical procedures and the intensity of postoperative pain. The global postoperative pain treatment market is anticipated to grow as a result of the development of numerous novel medications. Wide safety margins and advantageous characteristics are being used in the development of new medications.
The importance of non-opioid adjuncts and alternatives has increased for postoperative pain management. Examples of medications that have been popular in the postoperative pain market include intravenous (IV) acetaminophen, non-steroidal anti-inflammatory medicines (NSAIDs), magnesium, ketamine, dexmedetomidine, and liposomal bupivacaine. As a result, postoperative pain therapies now predominate in both emerging and developed markets due to innovative drugs, rising demand, better access, and improved pain management.
| Attribute | Details |
|---|---|
| Postoperative Pain Market Size (2023) | US$ 38.43 billion |
| Postoperative Pain Projected Market Value (2033) | US$ 63.8 billion |
| Global Postoperative Pain CAGR (2023 to 2033) | 5.2% |
| Market Share of Top 5 Countries | 65% |
Principal Consultant
Historically, the demand for postoperative pain drugs increased at a CAGR of 4.7% from 2018 to 2022. The market for postoperative pain was worth US$ 30.4 billion in 2018, the market surpassed US$ 36.53 billion by 2022. The demand for postoperative pain treatment is anticipated to increase in the future due to an increase in the number of traffic accidents, relative trauma injuries, and relative trauma injuries.
| Attribute | Valuation |
|---|---|
| 2025 | US$ 42.53 billion |
| 2028 | US$ 49.52 billion |
| 2032 | US$ 60.65 billion |
The market is anticipated to grow at a CAGR of 5.2% from 2023 to 2033, surpassing US$ 63.8 billion by 2033.
According to projections, the USA is likely to control 87.9% of the market for postoperative pain in North America by 2022. The adoption of opioid treatment is anticipated to lessen the opioid epidemic's rising prevalence in North America, particularly in the United States. For instance, more than 200 million opioid medications were prescribed and given to patients in the United States in 2018.
Furthermore, it is anticipated that the usage of postoperative pain medications would rise in this region due to the strong drug pipeline with effective medications up for FDA clearance. Patients' attitudes have improved in the United States as a result of better compliance with pain treatment suggestions. The country's demand for postoperative pain management pharmaceuticals is probably going to rise as a result of these figures, which will help the industry grow.
Several industry participants are putting strategic plans into action, which is helping the market expand. For instance, Allay Therapeutics, a clinical-stage biotechnology company that has been at the forefront of developing ultra-sustained analgesic products to revolutionize postsurgical pain management and recovery, released the first-ever clinical data demonstrating non-opioid pain relief lasting two weeks after a single administration in May 2021.
In 2022, Germany is anticipated to represent 26.9% of the market for postoperative pain in Europe. The market has grown due to the increasing prevalence and severity of postoperative pain, the launch of promising medications, an increase in surgical operations, and a high rate of pain procedures in developed nations like Germany.
Demand for postoperative pain medications is rising across Germany as opioid maintenance therapy (OMT) for treating opioid dependence (OD) becomes more widely accepted.
Due to the country's rising surgical rate, the postoperative pain market in South Korea is anticipated to grow at a 6.3% CAGR during the forecast period. Many manufacturers of painkillers are forming partnerships, and distribution agreements, and introducing postoperative painkillers in Korea. To increase their position in the worldwide market, major market players are concentrating on various business methods, such as obtaining product approval from regulatory bodies. On May 1, 2018, Grunenthal and Mundipharma struck a distribution and license deal, enabling Mundipharma to market and sell Grunenthal's Tramal (tramadol).
In Japan, opioids are usually prescribed for postoperative pain, but due to an increase in opioid use for non-medical reasons, governing bodies are pressuring doctors to prescribe non-opioid medications, which presents an opportunity for businesses to launch novel non-opioid medications. However, rising concerns about the opioid epidemic in the region and the rising burden of pain on providers of reimbursement are projected to limit the market's ability to grow to some extent.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By drug class, the opioids segment is predicted to grow at a 4% CAGR throughout the projection period to represent a significant proportion of 61.3% in 2022.
Adults who experience moderate to severe post-operative pain are typically treated with opioids, according to the NIH. As a result, over the past ten years, opioid use has increased. Opioid medications are recognized to be useful for treating postoperative pain and have demonstrated the capacity to support patients in accomplishing their clinical goals based on research studies and current trials.
High Demand for Oral Postoperative Pain Procedures
Oral postoperative pain is anticipated to hold 37.8% of the market in 2022 in terms of route of administration. For patients, especially the elderly, the oral route of administration is more convenient and widely accepted, which contributes to a bigger market share in the postoperative pain market. The high share of the market is ascribed to the segment's simplicity and patients' preference for oral drug administration.
Leading providers of postoperative pain medications are collaborating and acquiring other pharmaceutical firms as their primary approach for the creation of new product lines of pain medications. The demand for painkiller pharmaceuticals is increasing as key stakeholders put more emphasis on the creation of abuse-deterrent opioid drugs and the launch of extended-release non-opioid drugs for post-surgery pain. Similar to this, greater non-narcotic drug discovery and commercialization as well as growing awareness of post-surgery pain management are supporting market expansion.
The market is anticipated to expand as a result of rising acute disease prevalence and an increase in the elderly population in emerging economies. Manufacturers of painkilling drugs should expect great opportunities as patient awareness of procedures and operations grows and as research into pain management expands. Market expansion is anticipated to expand as government efforts to encourage improved postoperative pain management increase.
Recent Developments in the Postoperative Pain Industry:
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ billion for Value |
| Key Countries Covered |
|
| Key Market Segments Covered |
|
| Key Companies Profiled |
|
| Report Coverage |
|
| Customization & Pricing | Available upon Request |
The postoperative pain market size is anticipated to be US$ 38.43 billion in 2023.
The postoperative pain market size is assessed to be US$ 63.8 billion in 2033.
The postoperative pain market is expected to rise at a CAGR of 5.2% during the forecast period.
The United States is projected to lead the postoperative pain market over the forecast period.
1. Executive Summary | Postoperative Pain Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Opioids 5.3.2. NSAIDs 5.3.3. Local Anaesthetics 5.3.4. Tricyclic Antidepressants 5.3.5. Antiepileptic Drugs 5.3.6. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ million) Analysis By Route of Administration, 2018 to 2022 6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Route of Administration, 2023 to 2033 6.3.1. Oral 6.3.2. Intravenous 6.3.3. Intramuscular 6.3.4. Others 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ million) Analysis By Distribution Channel, 2018 to 2022 7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Distribution Channel, 2023 to 2033 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.3.3. Online Pharmacies 7.3.4. Others 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. Middle East and Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. The USA 9.2.1.2. Canada 9.2.2. By Drug Class 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Class 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. The United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Class 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Drug Class 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Class 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Drug Class 14.2.3. By Route of Administration 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Route of Administration 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug Class 15.2.3. By Route of Administration 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. The USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Class 16.1.2.2. By Route of Administration 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Class 16.2.2.2. By Route of Administration 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Class 16.3.2.2. By Route of Administration 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Class 16.4.2.2. By Route of Administration 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Class 16.5.2.2. By Route of Administration 16.5.2.3. By Distribution Channel 16.6. The United Kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Class 16.6.2.2. By Route of Administration 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Class 16.7.2.2. By Route of Administration 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Class 16.8.2.2. By Route of Administration 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Class 16.9.2.2. By Route of Administration 16.9.2.3. By Distribution Channel 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Class 16.10.2.2. By Route of Administration 16.10.2.3. By Distribution Channel 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Class 16.11.2.2. By Route of Administration 16.11.2.3. By Distribution Channel 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Class 16.12.2.2. By Route of Administration 16.12.2.3. By Distribution Channel 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Class 16.13.2.2. By Route of Administration 16.13.2.3. By Distribution Channel 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Class 16.14.2.2. By Route of Administration 16.14.2.3. By Distribution Channel 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Class 16.15.2.2. By Route of Administration 16.15.2.3. By Distribution Channel 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Class 16.16.2.2. By Route of Administration 16.16.2.3. By Distribution Channel 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Class 16.17.2.2. By Route of Administration 16.17.2.3. By Distribution Channel 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Class 16.18.2.2. By Route of Administration 16.18.2.3. By Distribution Channel 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Class 16.19.2.2. By Route of Administration 16.19.2.3. By Distribution Channel 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Class 16.20.2.2. By Route of Administration 16.20.2.3. By Distribution Channel 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Class 16.21.2.2. By Route of Administration 16.21.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Class 17.3.3. By Route of Administration 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Menarini Group 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. AcelRx Pharmaceuticals 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Trevena, Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Heron Therapeutics 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Innocoll Pharmaceuticals 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. DURECT Corporation 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Pacira Pharmaceuticals 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Baudax Bio 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Bausch & Lomb 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Novartis Pharmaceuticals 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.11. Eli Lilly and Company 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.12. Teva Pharmaceutical Industries Ltd. 18.1.12.1. Overview 18.1.12.2. Product Portfolio 18.1.12.3. Profitability by Market Segments 18.1.12.4. Sales Footprint 18.1.12.5. Strategy Overview 18.1.12.5.1. Marketing Strategy 18.1.13. Formosa Pharmaceuticals 18.1.13.1. Overview 18.1.13.2. Product Portfolio 18.1.13.3. Profitability by Market Segments 18.1.13.4. Sales Footprint 18.1.13.5. Strategy Overview 18.1.13.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Postoperative Pain Market
